TD Private Client Wealth’s Atara Biotherapeutics ATRA Stock Holding History

TD Private Client Wealth’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1	Closed	-$247	–	1108
2020 Q1	$247	Buy	+1	New	+$317	﹤0.01%	1025

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

TD Private Client Wealth's ATRA Position: Q2 2020 in Review

TD Private Client Wealth sold out of Atara Biotherapeutics (ATRA) in Q2 2020, closing a stake of 1 share — an estimated $247 sold.

TD Private Client Wealth first reported a position in ATRA in Q1 2020 and held it in 1 quarter. The position peaked at $247 in Q1 2020. 122 funds tracked by Wall St. Rank hold ATRA as of Q2 2020.

TD Private Client Wealth reported no remaining Atara Biotherapeutics position as of Q2 2020 after selling out during the quarter.
TD Private Client Wealth sold 1 Atara Biotherapeutics share in Q2 2020, an estimated $247.
TD Private Client Wealth first reported a position in Atara Biotherapeutics in Q1 2020 and held it in 1 quarter.
TD Private Client Wealth's Atara Biotherapeutics position peaked at $247 in Q1 2020.
122 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2020.

Based on TD Private Client Wealth's 13F filing for Q2 2020, filed 16 Aug 2024.